Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Assessment for frailty is useful for predicting morbidity in elderly patients undergoing colorectal cancer resection whose comorbidities are already optimized.
Tan KY, Kawamura YJ, Tokomitsu A, Tang T.
Am J Surg. 2011 Dec 16. [Epub ahead of print]
Related citations
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).
Pinto C, Di Fabio F, Maiello E, Pini S, Latiano T, Aschele C, Garufi C, Bochicchio A, Rosati G, Aprile G, Giaquinta S, Torri V, Bardelli A, Gion M, Martoni A.
Ann Oncol. 2011 Nov;22(11):2424-30. Epub 2011 Mar 8.
Prognostic significance and molecular associations of tumor growth pattern in colorectal cancer.
Morikawa T, Kuchiba A, Qian ZR, Mino-Kenudson M, Hornick JL, Yamauchi M, Imamura Y, Liao X, Nishihara R, Meyerhardt JA, Fuchs CS, Ogino S.
Ann Surg Oncol. 2012 Jun;19(6):1944-53. Epub 2011 Dec 22.
Decreased expression of 17β-hydroxysteroid dehydrogenase type 1 is associated with DNA hypermethylation in colorectal cancer located in the proximal colon.
Rawłuszko AA, Horbacka K, Krokowicz P, Jagodziński PP.
BMC Cancer. 2011 Dec 19;11:522.
The role of diet and physical activity in breast, colorectal, and prostate cancer survivorship: a review of the literature.
Davies NJ, Batehup L, Thomas R.
Br J Cancer. 2011 Nov 8;105 Suppl 1:S52-73. doi: 10.1038/bjc.2011.423. Review.
Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study.
Khan NF, Mant D, Carpenter L, Forman D, Rose PW.
Br J Cancer. 2011 Nov 8;105 Suppl 1:S29-37. doi: 10.1038/bjc.2011.420.
The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study.
Gormley JA, Hegarty SM, O'Grady A, Stevenson MR, Burden RE, Barrett HL, Scott CJ, Johnston JA, Wilson RH, Kay EW, Johnston PG, Olwill SA.
Br J Cancer. 2011 Nov 8;105(10):1487-94. doi: 10.1038/bjc.2011.408. Epub 2011 Oct 11.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase inhibitor augments radiotherapeutic efficacy in experimental colorectal cancer.
Miyatani T, Kurita N, Utsunomiya T, Iwata T, Nishioka M, Yoshikawa K, Higashijima J, Kashihara H, Takasu C, Fukushima M, Shimada M.
Cancer Lett. 2012 May 28;318(2):199-205. doi: 10.1016/j.canlet.2011.12.010. Epub 2011 Dec 13.
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H, Higgins B, Kolinsky K, Packman K, Bradley WD, Lee RJ, Schostack K, Simcox ME, Kopetz S, Heimbrook D, Lestini B, Bollag G, Su F.
Cancer Res. 2012 Feb 1;72(3):779-89. Epub 2011 Dec 16.
MiR-1 downregulation cooperates with MACC1 in promoting MET overexpression in human colon cancer.
Migliore C, Martin V, Leoni VP, Restivo A, Atzori L, Petrelli A, Isella C, Zorcolo L, Sarotto I, Casula G, Comoglio PM, Columbano A, Giordano S.
Clin Cancer Res. 2012 Feb 1;18(3):737-47. Epub 2011 Dec 16.
Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation.
Wong H, Alicke B, West KA, Pacheco P, La H, Januario T, Yauch RL, de Sauvage FJ, Gould SE.
Clin Cancer Res. 2011 Jul 15;17(14):4682-92. Epub 2011 May 24.
5-aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer.
Baan B, Dihal AA, Hoff E, Bos CL, Voorneveld PW, Koelink PJ, Wildenberg ME, Muncan V, Heijmans J, Verspaget HW, Richel DJ, Hardwick JC, Hommes DW, Peppelenbosch MP, van den Brink GR.
Gut. 2011 Dec 20. [Epub ahead of print]
An alternative way for epithelial-to-mesenchymal transition in colorectal cancer via EIF5A2?
Kolligs FT.
Gut. 2012 Apr;61(4):473-4. Epub 2011 Dec 16. No abstract available.
Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas.
Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, Birkenkamp-Demtröder K, Sørensen KD, Laurberg S, Orntoft TF, Andersen CL.
Int J Cancer. 2011 Dec 15;129(12):2855-66. doi: 10.1002/ijc.25951. Epub 2011 Apr 1.
Lymph node evaluation as a predictor of survival after resection for colorectal cancer.
Pappalardo G, Nunziale A.
J Am Coll Surg. 2012 Jan;214(1):125; author reply 125-6. No abstract available.
Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection.
Steinhagen E, Shia J, Markowitz AJ, Stadler ZK, Salo-Mullen EE, Zheng J, Lee-Kong SA, Nash GM, Offit K, Guillem JG.
J Am Coll Surg. 2012 Jan;214(1):61-7.
Colon cancer with microsatellite instability in a 13-year-old Hispanic male.
Adibe OO, Sharp RJ.
J Clin Oncol. 2012 Feb 10;30(5):e55-7. Epub 2011 Dec 19. No abstract available.
Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008.
Robbins AS, Siegel RL, Jemal A.
J Clin Oncol. 2012 Feb 1;30(4):401-5. Epub 2011 Dec 19.
Oxaliplatin-induced coronary vasospasm manifesting as Kounis syndrome: a case report.
Chang PH, Hung MJ, Yeh KY, Yang SY, Wang CH.
J Clin Oncol. 2011 Nov 1;29(31):e776-8. Epub 2011 Oct 3. No abstract available.
Synchronous tumor with diffuse large B-cell lymphoma and ameboma.
Takashima M, Kakimoto T, Saito H, Misaki S, Onishi Y, Kasugai T, Akuta K, Kasahara H, Yamamoto K, Doi Y, Ujiie H, Sugahara H, Hoshida Y, Sakoda H.
J Clin Oncol. 2011 Nov 1;29(31):e769-71. Epub 2011 Sep 26. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on